# Axogen Inc. (AXGN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $48.28, market value $2.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Axogen Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 10.3×**. Each dollar of revenue is priced at 10.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 10.1×**. The shares trade at 10.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.3%** (5-yr avg -5.2%). Free cash flow equals 0.3% of the market value, above its five-year average of -5.2%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Gross margin: 74.6%**. Axogen Inc. keeps 74.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -5.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -7.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -12.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -7.2%**. Return on all capital, debt included, is -7.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.1%**. Each dollar of assets produces -15.1% of profit.

## Growth
- **Revenue growth (1 yr): 20.2%** (3-yr 17.6%/yr, 5-yr 14.9%/yr). Revenue grew 20.2% over the last year, against 14.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -47.8%**. Earnings per share fell 47.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.38**. Debt is 0.38 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Axogen Inc. holds more cash than debt.
- **Altman Z-score: 18.49**. A Z-score of 18.49 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Axogen Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Axogen Inc.; the consensus is strong_buy, with an average price target of $53.90 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 213.5%** (YTD 47.5%, 3-mo 12.8%). The shares are up 213.5% over twelve months including dividends.
- **From 52-week high: -8.8%** (216.2% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.79** (volatility 53%). Beta of 0.79 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AXGN · Page: https://foliofundamentals.com/stocks/axgn

Not investment advice.